| 潘磊,陈培丰.魔芋葡甘露聚糖(KGM)对Lewis肺癌小鼠细胞免疫功能的影响[J].浙江中西医结合杂志,2016,26(4): |
| 魔芋葡甘露聚糖(KGM)对Lewis肺癌小鼠细胞免疫功能的影响 |
| Effect of immune function on Lewis lung cancer cell transplanted mice by Konjac glucomannan (KGM) |
| 投稿时间：2015-12-14 修订日期：2016-02-26 |
| DOI： |
| 中文关键词: 魔芋葡甘露聚糖 Lewis肺癌 T淋巴细胞 细胞因子 |
| 英文关键词:Konjac glucomannan (KGM),Lewis lung cancer, T-lymphocyte,Cytokine |
| 基金项目:浙江省自然科学(No.LY13H290012) |
|
| 摘要点击次数: 1131 |
| 全文下载次数: 24 |
| 中文摘要: |
| 目的 建立Lewis肺癌小鼠动物模型，观察中药蛇六谷主要成分—魔芋葡甘露聚糖（KGM）对小鼠免疫功能的影响。方法 建立Lewis肺癌小鼠动物模型后，随机分成：KGM高、中、低剂量组、生理盐水对照组和环磷酰胺组。建模第2天起，KGM高、中、低剂量按300mg/(kg.d)、200mg/(kg.d)、100mg/(kg.d)连续灌胃13天，生理盐水组以等剂量灌胃13天，环磷酰胺组按30mg/kg每周2次腹腔注射给药，共4次。第14天处死小鼠，取瘤体、脾脏称重并计算抑瘤率和脾脏指数，以MTS法检测脾脏中T淋巴细胞增殖活力，ELISA法检测脾细胞中IL-2的表达。结果 1.与对照组比较，各组瘤重均降低，其中CTX组、KGM中、高剂量组差异有统计学意义[（0.69±0.5g）、（1.71±0.95g）、（1.54±0.83g）比（2.51±1.11g），P＜0.05]；KGM低、中、高剂量组瘤重高于CTX组,差异有统计学意义[（2.15±0.88g）、（1.71±0.95g）、（1.54±0.83g）比（0.69±0.5g），P＜0.05]； 2.与对照组相比，CTX组脾脏指数降低[（2.73±1.19mg/g）比（4.61±0.69mg/g），P＜0.01]，KGM各剂量组脾脏指数升高，其中KGM中、高剂量组差异有统计学意义[（5.93±0.88mg/g）比（6.02±1.47mg/g）P＜0.01]；3.与对照组相比，T淋巴细胞增殖反应能力CTX组下降[（0.4055±0.2295）比（0.6125±0.0719）,P＜0.05]，KGM各剂量组增强，其中KGM高剂量组最强[（0.8198±0.0251）比（0.6125±0.0719）,P＜0.05]；与CTX组相比，KGM各剂量组的T淋巴细胞增殖反应能力均增强[（0.6338±0.1027）、（0.7±0.0966）、（0.8198±0.0251）比（0.4055±0.2295）,P＜0.05]。4.与对照组相比，CTX组IL-2下降[（434.43±44.64pg/mL）比（552.98±27.99pg/mL），P＜0.01]，KGM各剂量组上升[（664.69±30.46pg/mL）、（830.83±71.42pg/mL）、（1058.47±70.58pg/mL）比（552.98±27.99pg/mL），P＜0.01]，且KGM各剂量组两两比较，差异有统计学意义（P＜0.01）。结论 KGM可抑制Lewis肺癌小鼠肿瘤的生长，并可提高Lewis肺癌小鼠脾脏T淋巴细胞的增殖，上调脾细胞中IL-2的表达，提高其免疫功能，从而发挥可能的抗肿瘤作用。 |
| 英文摘要: |
| Objective Establishment of mouse Lewis lung cancer transplanted animal model, to observe the traditional Chinese medicine Rhizoma amorphophalli extract -konjac glucomannan( KGM ) effect on immune function in mice, investigate its mechanism. Methods Lewis lung cancer transplanted mice were established and then randomly assigned to one of the following 5 groups：KGM high dose group, KGM medium dose group, KGM low dose group, saline control group and cyclophospha- mide （CTX） group, Modeling of the second day, KGM high, medium, low dose group was treated with KGM 300mg／kg，200mg／kg，100mg／kg orally once daily for 13 days；The saline control group in a dose gavage for 13 days. CTX Group was treated with CTX 30mg/kg intraperitoneally 2 times weekly, a total of 4 times. The mice were sacrificed on the 14th day．The neoplasms and spleens were cut down , weighed and calculated the inhibition rate of tumor, spleen index, As determined by MTS method to detect the spleen T lymphocyte proliferation in the vitality, ELISA method to detect the expression of IL-2 spleen cells. The effects of KGM on the immunomodulatory and tumor therapy basing on the tumor bearing mice were evaluated. In addition, the probable mechanisms were analyzed．Results 1.TCompared with control group, each group tumor were lower, With CTX, KGM medium and high dose group difference was statistically significant[（0.69±0.5g）、（1.71±0.95g）、（1.54±0.83g）vs（2.51±1.11g），P＜0.05], KGM low, medium and high dose group of tumor weight higher than CTX group, the difference was statistically significant[（2.15±0.88g）、（1.71±0.95g）、（1.54±0.83g）vs（0.69±0.5g），P＜0.05];2.Compared with the control group, CTX group spleen index decreased[（2.73±1.19mg/g）vs（4.61±0.69mg/g），P＜0.01], KGM each dose group of spleen index increases,KGM medium and high dose group difference were statistically significant[（5.93±0.88mg/g）vs（6.02±1.47mg/g）P＜0.01].3. Compared with the control group, the T-lymphocytes proliferation response ability CTX group decreased [（0.4055±0.2295）vs（0.6125±0.0719）,P＜0.05], KGM each dose group enhanced, which the strongest was KGM high dose group[（0.8198±0.0251）vs（0.6125±0.0719）,P＜0.05].Compared to CTX group, KGM each dose group of T-lymphocytes proliferation response ability were enhanced[（0.6338±0.1027）、（0.7±0.0966）、（0.8198±0.0251）vs（0.4055±0.2295）,P＜0.05];4.IL-2 compared with the control group, CTX group decreased [（434.43±44.64pg/mL）vs（552.98±27.99pg/mL），P＜0.01], KGM each dose group increased[（664.69±30.46pg/mL）、（830.83±71.42pg/mL）、（1058.47±70.58pg/mL）vs（552.98±27.99pg/mL），P＜0.01], and each dose group of KGM pairwise comparison, the difference was statistically significant(P＜0.01).Conclusions konjac glucomannan can inhibit the growth of Lewis lung cancer tumors in mice, improve the Lewis lung cancer in mice spleen T-lymphocyte proliferation, raise spleen cells the expression of IL-2.To improvethe immune function, thus play a role in anti-tumor effect． |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
